Alexandrou, Constantinos
Al-Aqbi, Saif Sattar
Higgins, Jennifer A.
Boyle, William
Karmokar, Ankur
Andreadi, Catherine
Luo, Jin-Li
Moore, David A.
Viskaduraki, Maria
Blades, Matthew
Murray, Graeme I.
Howells, Lynne M.
Thomas, Anne
Brown, Karen
Cheng, Paul N.
Rufini, Alessandro
Article History
Received: 17 May 2018
Accepted: 2 August 2018
First Online: 14 August 2018
Competing Interests
: Paul N. Cheng is founder and CEO of Bio-Cancer Treatment and has a financial interest in rhArg1peg5000. All other authors declare no conflict of interest.